Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myovant Sciences Ltd.

Division of Roivant Sciences GmbH
www.myovant.com

Latest From Myovant Sciences Ltd.

Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.

Business Strategies Clinical Trials

Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio

Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.

Deals Research and Development Strategies

Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection

US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.

Gynecology & Urology Drug Review

True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal

Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

Clinical Trials Innovation
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences GmbH
  • Senior Management
  • Lynn Seely, MD, Pres. & CEO
    Frank Karbe, CFO
    Kim Sablich, Chief Commercial Officer
    Juan Camilo Arjona Ferreira, MD, CMO
  • Contact Info
  • Myovant Sciences Ltd.
    Phone: (650) 238-0250
    2000 Sierra Point Pkwy.
    5th Floor
    Brisbane, CA 94005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register